OncoZenge provides strategy update
On November 21st OncoZenge AB (publ) announced significant progress in the development of BupiZenge™, a novel non-opioid oral pain reliever. With that backdrop OncoZenge provides the following strategy update with focus on market potential and strategic partnering for accelerating BupiZenge™ towards market approval.As communicated in the company’s financial report for the 3rd quarter 2023 on October 31st, significant progress is being made towards the goals set out in the revised strategy communicated on September 9th. Furthermore, as communicated on November 21st, comprehensive analyses